Mercer Global Advisors Inc. ADV Takes $732,000 Position in Iqvia Holdings Inc (IQV)

Mercer Global Advisors Inc. ADV bought a new position in Iqvia Holdings Inc (NYSE:IQV) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,298 shares of the medical research company’s stock, valued at approximately $732,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. CENTRAL TRUST Co boosted its stake in shares of Iqvia by 1,150.0% in the fourth quarter. CENTRAL TRUST Co now owns 375 shares of the medical research company’s stock worth $44,000 after buying an additional 345 shares during the last quarter. Berman Capital Advisors LLC purchased a new stake in shares of Iqvia in the fourth quarter worth about $46,000. ERTS Wealth Advisors LLC purchased a new stake in shares of Iqvia in the fourth quarter worth about $46,000. Kaizen Advisory LLC boosted its stake in shares of Iqvia by 33.1% in the fourth quarter. Kaizen Advisory LLC now owns 450 shares of the medical research company’s stock worth $52,000 after buying an additional 112 shares during the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Iqvia in the fourth quarter worth about $59,000. Hedge funds and other institutional investors own 91.01% of the company’s stock.

In related news, Director Ronald A. Rittenmeyer sold 3,840 shares of the stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Evanisko sold 1,193 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,172,538 shares of company stock worth $587,465,163. Company insiders own 6.00% of the company’s stock.

Shares of IQV stock opened at $132.31 on Thursday. The company has a market cap of $26.96 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 1.72 and a beta of 0.85. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $146.10. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 1.57.

Iqvia (NYSE:IQV) last released its earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.03. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 earnings per share. On average, research analysts predict that Iqvia Holdings Inc will post 5.87 EPS for the current year.

A number of analysts have recently commented on IQV shares. Jefferies Financial Group upgraded Iqvia from a “hold” rating to a “buy” rating and upped their target price for the stock from $136.00 to $150.00 in a research note on Friday, January 18th. UBS Group set a $170.00 price target on Iqvia and gave the stock a “buy” rating in a research report on Friday, February 15th. Barclays increased their price target on Iqvia from $160.00 to $167.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Goldman Sachs Group upgraded Iqvia from a “buy” rating to a “conviction-buy” rating in a research report on Friday, January 11th. Finally, Wells Fargo & Co increased their price target on Iqvia from $140.00 to $160.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $146.88.

WARNING: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2019/04/18/mercer-global-advisors-inc-adv-takes-732000-position-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What is the Rule of 72?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.